Comment on "A series of microRNA in the chromosome 14q32.2 maternally imprinted region related to progression of non-alcoholic fatty liver disease in a mouse model"

References

[1] Basaranoglu M,Sabuncu T.Fructose as a key player in the development of fatty liver disease..World J Gastroenterol2013;19:1166-72 PMCID:PMC3587472

[2] Day CP.Steatohepatitis: a tale of two "hits"?.Gastroenterology1998;114:842-5

[3] Tilg H.Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis..Hepatology2010;52:1836-46

[4] Sanyal AJ,Kleiner DE,Chalasani N,Ratziu V.Endpoints and clinical trial design for nonalcoholic steatohepatitis..Hepatology2011;54:344-53 PMCID:PMC4014460

[5] Bartel DP.MicroRNAs: genomics, biogenesis, mechanism, and function..Cell2004;116:281-97

[6] Gregory RI,Cooch N.Human RISC couples microRNA biogenesis and posttranscriptional gene silencing..Cell2005;123:631-40

[7] Cheung O,Eicken C,Mirshahi F,Kellum JM,Luketic VA.Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression..Hepatology2008;48:1810-20 PMCID:PMC2717729

[8] Pogribny IP,Tryndyak VP,Ross SA,Beland FA.Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice..Lab Invest2010;90:1437-46 PMCID:PMC4281935

[9] Alisi A,Bruscalupi G,Panera N,Leoni S,Masotti A.Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease..Lab Invest2011;91:283-93

[10] Choi SE,Seok S,Yu E,Kang Y,Kemper B.Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT..Aging Cell2013;12:1062-72 PMCID:PMC3838500

[11] Okamoto K,Okamoto T,Miyoshi K,Kato J,Sugihara TA,Hino K.A series of microrna in the chromosome 14q32.2 maternally imprinted region related to progression of non-alcoholic fatty liver disease in a mouse model..PLoS One2016;11:e0154676

[12] Ha J,Kim J.AMPK and autophagy in glucose/glycogen metabolism..Mol Aspects Med2015;46:46-62

[13] Di Fazio P,Jabari S,Montalbano R,Slater EP,Illig R,Wissniowski TT.Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer..Oncotarget2016;

[14] Mahgoub A.MicroRNAs in the evaluation and potential treatment of liver diseases..J Clin Med2016;5:52 PMCID:PMC4882481

[15] Kanda M,Kodera Y.Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma..World J Gastroenterol2015;21:10584-97 PMCID:PMC4588080

[16] Damanakis AI,Wunderlich A,Wissniowski TT,Di Fazio P.MicroRNAs let7 expression in thyroid cancer: correlation with their deputed targets HMGA2 and SLC5A5..J Cancer Res Clin Oncol2016;142:1213-20

[17] Henrici A,Neureiter D,Stiewe T,Quint K,Di Fazio P.The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines..Mol Carcinog2015;54:585-97

[18] Di Fazio P,Neureiter D,Schmidt A,Quint K.Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines..Exp Cell Res2012;318:1832-43

[19] Khawaja MR,Madhusudanannair V,Hong D,Ng CS,Janku F,Tsimberidou A,Meric-Bernstam F,Naing A.Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers..Cancer Chemother Pharmacol2016;77:973-7

[20] Provinciali N,Cazzaniga M,Dunn BK.Metformin: risk-benefit profile with a focus on cancer..Expert Opin Drug Saf2015;14:1573-85

[21] Xu H,Liu YX,Shou QY,Ruo R.Metformin improves hepatic IRS2/PI3K/Akt signaling in insulin resistant rats of NASH and cirrhosis..J Endocrinol2016;229:133-44